Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian AD consensus
Source-attributed clinical priorities
- Confirm an atopic pattern while considering contact dermatitis, scabies, psoriasis, fungal infection and immune deficiency.
- Use regular emollient care, trigger reduction and topical anti-inflammatory treatment matched to site and severity.
- Recognize bacterial or herpetic infection, sleep loss and treatment burden and refer severe or uncontrolled disease.
- Written instructions should specify which topical product goes on which body site and for how long.
sources for this section:Canadian AD consensus
Practical assessment and management workflow
1
Assess distribution, severity, itch, sleep, infection, triggers, occupational exposure and previous treatment.
2
Examine for atopic morphology and alternatives such as contact dermatitis, scabies, psoriasis or tinea.
3
Use liberal emollient care and site-appropriate topical anti-inflammatory treatment with application teaching.
4
Review adherence and potency before escalation and refer severe or treatment-refractory disease.
sources for this section:Canadian AD consensus
Safety, red flags and urgent escalation
- Painful monomorphic vesicles, fever or rapidly worsening eczema suggests eczema herpeticum.
- Treat spreading bacterial infection when clinically present, not colonization alone.
- Avoid potent topical corticosteroid on thin skin without a defined short course and review.
sources for this section:Canadian AD consensus
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian AD consensus
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian AD consensus
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Atopic Dermatitis Consensus PanelCanadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapiesaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.